



Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

Information for the public Published: 30 March 2022

www.nice.org.uk

Sotorasib (Lumykras) is available through the Cancer Drugs Fund. It is a possible treatment for locally advanced or metastatic non-small-cell lung cancer in adults if:

- their tumours have a mutation called KRAS G12C
- they have had, or cannot tolerate, platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy.

More evidence on sotorasib is being collected. After this NICE will decide whether or not to recommend sotorasib for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

If you are not eligible for sotorasib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about <u>making decisions about your care</u>.

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The NHS website may be a good place to find out more.

These organisations can give you advice and support:

- Roy Castle Lung Cancer Foundation, 0333 323 7200
- Lung Cancer Nursing UK (LCNUK), 01675 477 607
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000

You can also get support from your local Healthwatch.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4502-3